Article

Brain-Gut Axis: From Basic Understanding to Treatment of IBS and Related Disorders

Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Journal of pediatric gastroenterology and nutrition (Impact Factor: 2.87). 10/2011; 54(4):446-53. DOI: 10.1097/MPG.0b013e31823d34c3
Source: PubMed

ABSTRACT The present review describes advances in understanding the mechanisms and provide an update of present and promising therapy directed at the gut or the brain in the treatment of irritable bowel syndrome (IBS). The diagnosis of IBS typically is based on identification of symptoms, such as the Rome III criteria for IBS in adults and children. The criteria are similar in children and adults. The focus of the present review is the bowel dysfunction associated with IBS.

2 Followers
 · 
237 Views
  • Source
    • "the advent of a number of neurophysiological techniques, that these interactions have been studied non-invasively in vivo. This increased understanding has led to the development of the concept of the brain–gut axis, a bidirectional intercommunication between the gut and the brain, providing an explanation of both normal activity and acute and chronic perturbations of GI function (Camilleri & Di Lorenzo, 2012). Moreover, this model of circuitous communication underpins the biopsychosocial concept, first explicitly formulated by George Engel in the late 1970s, postulates that all illnesses, but especially in GI disorders, result from a complex reciprocal interaction between biological/genetic, psychological and social factors (Engel, 1977). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Common human experience shows that stress and anxiety may modulate gut function. Such observations have been combined with an increasing experimental evidence base have culminated in the concept of the brain-gut axis. Nevertheless, it has not been until recently that the gut and its attendant components, have been considered to influence higher cerebral function and behaviour per se. Moreover, the proposal that the gut and the bacteria contained therein (collectively referred to as the microbiota) can modulate mood and behaviours, has an increasing body of supporting evidence, albeit largely derived from animal studies. The gut microbiota is a dynamic and diverse ecosystem and forms a symbiotic relationship with the host. Herein we describe the components of the gut microbiota and mechanisms by which it can influence neural development, complex behaviours and nociception. Furthermore, we propose the novel concept of a ‘state of gut’ rather than a state of mind, particularly in relation to functional bowel disorders. Finally, we address the exciting possibility that the gut microbiota may offer a novel area of therapeutic intervention across a diverse array of both affective and GI disorders.This article is protected by copyright. All rights reserved
    The Journal of Physiology 03/2014; 592(14). DOI:10.1113/jphysiol.2013.270389 · 4.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Irritable bowel syndrome (IBS) and chronic constipation (CC) are common problems worldwide and are associated with significant impact on activities of daily living and quality of life. Recent interest, in IBS in particular, has focused on the potential roles of the microbiota and its interaction with the host's immune system. Recently, high-quality clinical trials have been performed on prebiotics and probiotics in IBS or CC. Although strategies that seek to modify the microbiota, such as the use of probiotics, offer much promise in IBS and CC, more high-quality trials and, studies of longer duration are required.
    Gastroenterology clinics of North America 12/2012; 41(4):805-19. DOI:10.1016/j.gtc.2012.08.005 · 1.92 Impact Factor
  • Article: Linaclotide
    [Show abstract] [Hide abstract]
    ABSTRACT: Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The February 2013 monograph topics are tofacitinib, cabozantinib, suvorexant, vortioxetine, and apremilast. The DUE/MUE is on tofacitinib.
    Hospital pharmacy 02/2013; 48(2):143-52. DOI:10.1310/hpj4802-143.test
Show more